JP7498661B2 - 経口免疫療法の方法 - Google Patents
経口免疫療法の方法 Download PDFInfo
- Publication number
- JP7498661B2 JP7498661B2 JP2020524388A JP2020524388A JP7498661B2 JP 7498661 B2 JP7498661 B2 JP 7498661B2 JP 2020524388 A JP2020524388 A JP 2020524388A JP 2020524388 A JP2020524388 A JP 2020524388A JP 7498661 B2 JP7498661 B2 JP 7498661B2
- Authority
- JP
- Japan
- Prior art keywords
- peanut
- subject
- level
- specific ige
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 383
- 238000009169 immunotherapy Methods 0.000 title claims description 192
- 241001553178 Arachis glabrata Species 0.000 claims description 1095
- 235000020232 peanut Nutrition 0.000 claims description 1095
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 1094
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 1094
- 235000018262 Arachis monticola Nutrition 0.000 claims description 1094
- 238000011282 treatment Methods 0.000 claims description 543
- 206010016946 Food allergy Diseases 0.000 claims description 249
- 208000008267 Peanut Hypersensitivity Diseases 0.000 claims description 230
- 201000010853 peanut allergy Diseases 0.000 claims description 225
- 239000000203 mixture Substances 0.000 claims description 212
- 230000002009 allergenic effect Effects 0.000 claims description 173
- 206010020751 Hypersensitivity Diseases 0.000 claims description 169
- 238000012544 monitoring process Methods 0.000 claims description 135
- 208000024891 symptom Diseases 0.000 claims description 132
- 208000030961 allergic reaction Diseases 0.000 claims description 106
- 238000012423 maintenance Methods 0.000 claims description 67
- 230000000977 initiatory effect Effects 0.000 claims description 66
- 102000004169 proteins and genes Human genes 0.000 claims description 66
- 108090000623 proteins and genes Proteins 0.000 claims description 66
- 208000026935 allergic disease Diseases 0.000 claims description 54
- 230000007815 allergy Effects 0.000 claims description 46
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 42
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 42
- 230000003111 delayed effect Effects 0.000 claims description 42
- 229960005139 epinephrine Drugs 0.000 claims description 42
- 230000002829 reductive effect Effects 0.000 claims description 33
- 230000002496 gastric effect Effects 0.000 claims description 27
- 238000004448 titration Methods 0.000 claims description 26
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims description 20
- 208000003455 anaphylaxis Diseases 0.000 claims description 20
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims description 20
- 208000004998 Abdominal Pain Diseases 0.000 claims description 19
- 206010047700 Vomiting Diseases 0.000 claims description 19
- 230000008673 vomiting Effects 0.000 claims description 19
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 18
- 230000036783 anaphylactic response Effects 0.000 claims description 18
- 238000003018 immunoassay Methods 0.000 claims description 17
- 230000004044 response Effects 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 13
- 108090000790 Enzymes Proteins 0.000 claims description 13
- 238000011285 therapeutic regimen Methods 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000009610 hypersensitivity Effects 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 230000036772 blood pressure Effects 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 230000036387 respiratory rate Effects 0.000 claims description 4
- 239000013566 allergen Substances 0.000 description 71
- 208000010668 atopic eczema Diseases 0.000 description 45
- 239000013568 food allergen Substances 0.000 description 44
- 230000000172 allergic effect Effects 0.000 description 43
- 235000013305 food Nutrition 0.000 description 40
- 210000002966 serum Anatomy 0.000 description 34
- 208000004262 Food Hypersensitivity Diseases 0.000 description 31
- 235000020932 food allergy Nutrition 0.000 description 31
- 238000011269 treatment regimen Methods 0.000 description 19
- 239000005557 antagonist Substances 0.000 description 17
- 239000000090 biomarker Substances 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 229940124597 therapeutic agent Drugs 0.000 description 15
- 235000013312 flour Nutrition 0.000 description 12
- 239000000902 placebo Substances 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 11
- 239000012071 phase Substances 0.000 description 10
- 230000002411 adverse Effects 0.000 description 9
- 206010067484 Adverse reaction Diseases 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 230000006838 adverse reaction Effects 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000003090 exacerbative effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000010181 skin prick test Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 206010002199 Anaphylactic shock Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 2
- 201000010859 Milk allergy Diseases 0.000 description 2
- 208000002366 Nut Hypersensitivity Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 230000003832 immune regulation Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 2
- 201000010854 nut allergy Diseases 0.000 description 2
- 235000014571 nuts Nutrition 0.000 description 2
- 229960000470 omalizumab Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229950000321 benralizumab Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229950002183 lebrikizumab Drugs 0.000 description 1
- 229950009923 ligelizumab Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940109690 nucala Drugs 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 229940121324 romilkimab Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229950000835 tralokinumab Drugs 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940099073 xolair Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580999P | 2017-11-02 | 2017-11-02 | |
| US62/580,999 | 2017-11-02 | ||
| US201862631406P | 2018-02-15 | 2018-02-15 | |
| US62/631,406 | 2018-02-15 | ||
| US201862637903P | 2018-03-02 | 2018-03-02 | |
| US62/637,903 | 2018-03-02 | ||
| US201862674478P | 2018-05-21 | 2018-05-21 | |
| US62/674,478 | 2018-05-21 | ||
| PCT/US2018/058777 WO2019089978A1 (en) | 2017-11-02 | 2018-11-01 | Methods of oral immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501763A JP2021501763A (ja) | 2021-01-21 |
| JP2021501763A5 JP2021501763A5 (https=) | 2021-12-09 |
| JP7498661B2 true JP7498661B2 (ja) | 2024-06-12 |
Family
ID=66332382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020524388A Active JP7498661B2 (ja) | 2017-11-02 | 2018-11-01 | 経口免疫療法の方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11369676B2 (https=) |
| EP (1) | EP3703743A4 (https=) |
| JP (1) | JP7498661B2 (https=) |
| KR (1) | KR102753602B1 (https=) |
| CN (1) | CN111344010A (https=) |
| AU (1) | AU2018358125B2 (https=) |
| CA (1) | CA3080601A1 (https=) |
| MX (1) | MX2020004683A (https=) |
| WO (1) | WO2019089978A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| WO2014159607A1 (en) | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Manufacture of peanut formulations for oral desensitization |
| AU2015306683B2 (en) | 2014-08-25 | 2021-11-25 | Societe Des Produits Nestle S.A. | Egg protein formulations and methods of manufacture thereof |
| EP4545077A1 (en) | 2017-12-06 | 2025-04-30 | Prollergy Corporation | Composition and method for reducing allergic response |
| US11406563B2 (en) | 2018-07-27 | 2022-08-09 | Société des Produits Nestlé S.A. | Oral immunotherapy unit dose dispensing systems and methods |
| WO2020037151A1 (en) | 2018-08-16 | 2020-02-20 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy with maintenance dose |
| WO2020100024A1 (en) * | 2018-11-12 | 2020-05-22 | Murdoch Childrens Research Institute | Method and system |
| CA3123605A1 (en) | 2018-12-20 | 2020-06-25 | Aimmune Therapeutics, Inc. | Peanut oral immunotherapy dosing schedule for missed doses |
| EP3965815A4 (en) * | 2019-05-10 | 2023-05-31 | Société des Produits Nestlé S.A. | METHOD OF IMPROVING THE QUALITY OF LIFE IN A PEANUT ALLERGY PATIENT |
| CA3162040A1 (en) * | 2019-12-23 | 2021-07-01 | Bronwyn POLLOCK | Pharmaceutical compositions |
| AU2020412960A1 (en) * | 2019-12-23 | 2022-06-16 | Prota Therapeutics Pty Ltd | Allergy treatment |
| BR112022026945A2 (pt) | 2020-07-01 | 2023-03-07 | Nestle Sa | Determinação de equipe médica para imunoterapia oral |
| WO2022089595A1 (en) * | 2020-10-30 | 2022-05-05 | Oneness Biotech Co., Ltd. | Biomarkers for ige-mediated diseases |
| JP2024509087A (ja) * | 2021-02-24 | 2024-02-29 | オールアダプト イミュノセラピューティクス，インコーポレイテッド | アレルギーの治療方法 |
| US20250342925A1 (en) * | 2022-04-15 | 2025-11-06 | Samsung Life Public Welfare Foundation | Method for providing food allergy treatment service using oral immunotherapy, computer program stored in recording medium to implement method, and system |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090111702A1 (en) | 2004-04-06 | 2009-04-30 | Mount Sinai School Of Medicine Office Of Industrial Liason | Methods of determining allergen response using microarray immunoassay techniques |
| JP2014509606A (ja) | 2011-03-17 | 2014-04-21 | ケンブリッジ エンタープライズ リミティッド | ピーナッツアレルギーの治療 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3809767A (en) | 1969-05-12 | 1974-05-07 | Griffith Laboratories | Methods of making vegetable protein concentrates |
| EP1272213B1 (en) | 2000-04-06 | 2006-03-08 | SEER Pharmaceuticals, LLC. | Microbial delivery system |
| US7820175B2 (en) | 2004-03-19 | 2010-10-26 | Herbal Spring, Llc | Herbal therapy for the treatment of food allergy |
| MX2011006353A (es) | 2008-12-19 | 2011-07-13 | Merz Pharma Gmbh & Co Kgaa | Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos. |
| UY33472A (es) | 2010-06-30 | 2012-01-31 | Novartis Ag | ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?. |
| DE102011086048A1 (de) | 2011-04-07 | 2012-10-11 | Continental Teves Ag & Co. Ohg | Gehäuseseitige Trennschicht zur Stressentkopplung von vergossenen Elektroniken |
| WO2014159607A1 (en) | 2013-03-14 | 2014-10-02 | Allergen Research Corporation | Manufacture of peanut formulations for oral desensitization |
| US9492535B2 (en) * | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| US20150320706A1 (en) * | 2014-05-12 | 2015-11-12 | Chiesi Farmaceutici S.P.A. | Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy |
| AU2015306683B2 (en) | 2014-08-25 | 2021-11-25 | Societe Des Produits Nestle S.A. | Egg protein formulations and methods of manufacture thereof |
| EP3568027A4 (en) | 2017-01-13 | 2020-11-11 | Aimmune Therapeutics, Inc. | WALNUT FLOUR MANUFACTURING PROCESSES AND FORMULATIONS FOR ORAL IMMUNOTHERAPY |
-
2018
- 2018-11-01 JP JP2020524388A patent/JP7498661B2/ja active Active
- 2018-11-01 CA CA3080601A patent/CA3080601A1/en active Pending
- 2018-11-01 US US16/178,502 patent/US11369676B2/en active Active
- 2018-11-01 MX MX2020004683A patent/MX2020004683A/es unknown
- 2018-11-01 EP EP18871949.6A patent/EP3703743A4/en active Pending
- 2018-11-01 KR KR1020207015239A patent/KR102753602B1/ko active Active
- 2018-11-01 CN CN201880071608.XA patent/CN111344010A/zh active Pending
- 2018-11-01 AU AU2018358125A patent/AU2018358125B2/en active Active
- 2018-11-01 WO PCT/US2018/058777 patent/WO2019089978A1/en not_active Ceased
-
2022
- 2022-05-24 US US17/752,639 patent/US12357688B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090111702A1 (en) | 2004-04-06 | 2009-04-30 | Mount Sinai School Of Medicine Office Of Industrial Liason | Methods of determining allergen response using microarray immunoassay techniques |
| JP2014509606A (ja) | 2011-03-17 | 2014-04-21 | ケンブリッジ エンタープライズ リミティッド | ピーナッツアレルギーの治療 |
Non-Patent Citations (2)
| Title |
|---|
| J ALLERGY CLIN IMMUNOL，2014年，Vol. 133，pp. 468-475 |
| J ALLERGY CLIN IMMUNOL，2017年01月，Vol. 139，pp. 173-181 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018358125A1 (en) | 2020-05-14 |
| US20190167785A1 (en) | 2019-06-06 |
| CA3080601A1 (en) | 2019-05-09 |
| MX2020004683A (es) | 2020-08-13 |
| US11369676B2 (en) | 2022-06-28 |
| EP3703743A4 (en) | 2021-12-08 |
| CN111344010A (zh) | 2020-06-26 |
| EP3703743A1 (en) | 2020-09-09 |
| US12357688B2 (en) | 2025-07-15 |
| AU2018358125B2 (en) | 2025-09-04 |
| WO2019089978A1 (en) | 2019-05-09 |
| JP2021501763A (ja) | 2021-01-21 |
| KR20200083526A (ko) | 2020-07-08 |
| KR102753602B1 (ko) | 2025-01-10 |
| US20220288196A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7498661B2 (ja) | 経口免疫療法の方法 | |
| Vickery et al. | Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective | |
| Nachshon et al. | Efficacy and safety of sesame oral immunotherapy—a real-world, single-center study | |
| Anagnostou et al. | Efficacy and safety of high‐dose peanut oral immunotherapy with factors predicting outcome | |
| JP7536035B2 (ja) | ピーナツに対する経口免疫療法における全身性アレルギー応答リスク評価 | |
| Kim et al. | Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization | |
| Wang et al. | Food allergy | |
| AU2012228033B2 (en) | Treatment for peanut allergy | |
| Vickery et al. | Current and future treatment of peanut allergy | |
| Wang et al. | Clinical manifestations of pediatric food allergy: a contemporary review | |
| McGowan et al. | Sublingual (SLIT) versus oral immunotherapy (OIT) for food allergy | |
| Byrne et al. | How do we know when peanut and tree nut allergy have resolved, and how do we keep it resolved? | |
| CN113966229A (zh) | 用于改善花生过敏患者的生活质量的方法 | |
| Yahia et al. | Oral immunotherapy for children with a high-threshold peanut allergy | |
| Porcaro et al. | Anaphylaxis to cutaneous exposure to bovine colostrum based cream | |
| US20250011474A1 (en) | ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES | |
| Chiewchalermsri et al. | Randomized, double-blind, placebo-controlled trial of vitamin D supplementation in the build-up phase of house dust mite-specific immunotherapy | |
| Kattan | Oral food challenges in routine clinical practice | |
| Nagakura et al. | Randomized Trial of Milk Oral Immunotherapy: Fixed Low-Dose vs Escalation to Medium-Dose | |
| Epstein‐Rigbi et al. | Decreased Severity of Oral Immunotherapy Induced Gastrointestinal Eosinophilic Reactions Following Revisions in Milk‐Treatment Protocol | |
| Reier-Nilsen | High-dose oral immunotherapy in children with anaphylaxis to peanut | |
| Cosper et al. | 7 to 11: Food Allergy Treatment Therapies | |
| Tirumalasetty et al. | Monitoring clinical response to immunomodulatory treatments | |
| Li | Immunological Humoral and Cellular Activation Profiles in the Low Dose Multi Allergen Oral Immunotherapy Trial | |
| Roberts et al. | Developments in the field of allergy in 2016 through the eyes of Clinical and Experimental Allergy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200708 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211029 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211029 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20211130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221109 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230206 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20230206 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230508 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230808 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231031 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240207 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240507 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240531 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7498661 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |